13F Holdings
中文EN

ELAN Elanco Animal Health Inc

Pharmaceutical Preparations · NYSE · SEC CIK 1739104 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.1%
TTM net income YoY-508.3%
TTM EPS YoY-528.6%
Revenue 3-yr CAGR5.7%
Net income 3-yr CAGR—

Margins

Gross margin56.2%
Operating margin—
Net margin-2.9%
FCF margin7.9%
EBITDA margin—

Returns

ROE-2.2%
ROA-1.1%
ROIC (approx.)—
Asset turnover0.38x

Leverage & solvency

Liabilities / assets50.3%
Debt / equity0.56x
Current ratio2.09x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-4.18x
Accruals ratio-5.7%
Payout ratio—
Capex / revenue4.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$4.71B$4.44B$4.42B$4.41B$4.76B
Cost of revenue$2.12B$2.00B$1.93B$1.91B$2.13B
Gross profit$2.59B$2.44B$2.49B$2.50B$2.63B
R&D expense$368.00M$344.00M$327.00M$321.00M$369.00M
SG&A expense$1.43B$1.31B$1.28B$1.26B$1.40B
Interest expense——$277.00M$241.00M$236.00M
Pretax income-$224.00M$488.00M-$1.20B-$72.00M-$571.00M
Income tax$8.00M$150.00M$36.00M$6.00M-$88.00M
Net income-$232.00M$338.00M-$1.23B-$78.00M-$483.00M
EPS (basic)-0.470.68-2.50-0.16-0.99
EPS (diluted)-0.470.68-2.50-0.16-0.99
Weighted avg. shares (diluted)496.40M497.30M492.30M488.30M487.20M
Balance sheet
Cash & equivalents$545.00M$468.00M$352.00M$345.00M$638.00M
Receivables$873.00M$805.00M$842.00M$797.00M$833.00M
Inventory$1.74B$1.57B$1.74B$1.54B$1.37B
Current assets$3.46B$3.21B$3.41B$3.28B$3.27B
PP&E, net$1.41B$993.00M$1.03B$999.00M$1.05B
Goodwill$4.78B$4.41B$5.09B$5.99B$6.17B
Intangibles$3.41B$3.68B$4.49B$4.84B$5.59B
Total assets$13.36B$12.61B$14.36B$15.49B$16.48B
Current liabilities$1.60B$1.31B$1.24B$1.70B$1.65B
Short-term debt$74.00M$44.00M$38.00M$388.00M$294.00M
Long-term debt$3.94B$4.28B$5.74B$5.45B$6.03B
Total debt$4.02B$4.32B$5.77B$5.84B$6.32B
Total liabilities$6.81B$6.52B$8.14B$8.20B$8.97B
Shareholders' equity$6.55B$6.10B$6.22B$7.29B$7.51B
Net debt$3.47B$3.85B$5.42B$5.49B$5.68B
Shares outstanding496.98M494.45M492.85M474.24M473.12M
Cash flow statement
Operating cash flow$560.00M$541.00M$271.00M$452.00M$483.00M
Capital expenditure$276.00M$147.00M$140.00M$171.00M$159.00M
Free cash flow$284.00M$394.00M$131.00M$281.00M$324.00M
Investing cash flow-$279.00M$1.16B-$169.00M-$179.00M-$530.00M
Financing cash flow-$275.00M-$1.49B-$83.00M-$549.00M$210.00M
Depreciation & amortization$680.00M$662.00M$694.00M$682.00M$716.00M
Stock-based compensation$68.00M$55.00M$46.00M$59.00M$66.00M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.